Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04367077
Previous Study | Return to List | Next Study

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) (MACoVIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04367077
Recruitment Status : Recruiting
First Posted : April 29, 2020
Last Update Posted : January 25, 2021
Sponsor:
Information provided by (Responsible Party):
Athersys, Inc

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Multicenter investigation featuring an open-label lead-in followed by a double blinded, randomized, placebo-controlled Phase 2/3 part to evaluate the safety and efficacy of MultiStem therapy in subjects with moderate to severe Acute Respiratory Distress Syndrome (ARDS) due to COVID-19.

Condition or disease Intervention/treatment Phase
ARDS Biological: MultiStem Biological: Placebo Phase 2 Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)
Actual Study Start Date : April 28, 2020
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: MultiStem Biological: MultiStem
intravenous infusion
Placebo Comparator: Placebo Biological: Placebo
intravenous infusion


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Ventilator-Free Days [ Time Frame: Day 0 through Day 28. ]
  2. Safety and Tolerability as measured by the incidence of treatment-emergent adverse events as assessed by CTCAE v5.0. [ Time Frame: Day 28 ]

Secondary Outcome Measures :
  1. All-cause mortality [ Time Frame: Day 60 ]
  2. Ranked hierarchical composite outcome of alive and ventilator-free [ Time Frame: Day 28 ]
  3. Ventilator-free days [ Time Frame: Day 0 through Day 60 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Diagnosis of new acute-onset moderate to severe ARDS, as defined by the Berlin criteria and Clinical diagnosis of COVID-19,

Exclusion Criteria:

Moribund subject who, in the opinion of the Investigator, is not expected to survive at least 48 hours and End-stage severe chronic lung disease

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04367077


Contacts
Layout table for location contacts
Contact: Athersys Clinical Trials Group 2164263597 macovia@athersys.com

Locations
Layout table for location information
United States, Illinois
Athersys Investigational Site 107 Recruiting
Chicago, Illinois, United States, 60601
Contact: Athersys Clinical Trials Group    216-426-3597    macovia@athersys.com   
United States, Ohio
Athersys Investigational Site 103 Recruiting
Akron, Ohio, United States, 44304
Contact: Athersys Clinical Trials Group    216-426-3597    macovia@athersys.com   
Athersys Investigational Site 101 Recruiting
Cleveland, Ohio, United States, 44106
Contact: Athersys Clinical Trials Group    216-426-3597    macovia@athersys.com   
Athersys Investigational Site 102 Recruiting
Cleveland, Ohio, United States, 44109
Contact: Athersys Clinical Trials Group    216-426-3597    macovia@athersys.com   
Sponsors and Collaborators
Athersys, Inc
Investigators
Layout table for investigator information
Study Director: Anthony Ting, PhD Athersys, Inc
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Athersys, Inc
ClinicalTrials.gov Identifier: NCT04367077    
Other Study ID Numbers: B04-03
First Posted: April 29, 2020    Key Record Dates
Last Update Posted: January 25, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Athersys, Inc:
COVID19
respiratory distress
adult stem cells